Scientists at Duke-NUS Medical School have uncovered why some pancreatic and colorectal cancers fail to respond to Wnt inhibitors, a promising new class of cancer drugs currently under development for these cancers. Their discovery, published in Science Advances, not only offers a new cancer therapy target but also a potential screening tool to identify those patients who will not benefit from this new therapy once it becomes available.
Scientists uncover key resistance mechanism to Wnt inhibitors in pancreatic and colorectal cancers
Posted in biotech/medical